VACCClinical Trials•globenewswire•
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
Sentiment:Positive (70)
Summary
(VACC) VAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant Population to Protect Against Invasive Pneumococcal Disease (IPD)
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 3, 2025 by globenewswire